A Study of Ramucirumab and Docetaxel in Participants With Solid Tumors

Clinical trial NCT01567163 · COMPLETED

Trial details

NCT number: NCT01567163
Sponsor: Eli Lilly and Company
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Malignant Solid Tumor

Start date: 2012-07-01
Primary completion: 2012-12-01
Enrollment: 22

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.